Tina S. Nova
Independent DirectorDr. Tina S. Nova, Ph.D., is Independent Director of Tang Capital Acquisition Corp. from August 14, 2026. Dr. Nova is Independent Director of Aurinia Pharmaceuticals Inc. from May 15, 2025. Dr. Nova was Director since December 2024 until 2026 at Truvian Sciences, Inc. She serves as an Independent Director at Azenta, Inc. since January 31, 2023. She served as the General Manager of Decipher Urologic Cancers at Veracyte, Inc. February 2023 until September 3, 2023 and was its President of CLIA U.S. Business since January 6, 2022 until February 2023 and served on Board of Directors from November 2015 to February 2021. She leads all aspects of Veracyte's CLIA U.S. business including market development, product marketing, payer reimbursement, sales and operations for all diagnostic tests that are performed in the Veracyte, Inc's laboratories and physicians and their patients in the United States and was served as its General Manager of Thyroid and Urologic Cancers from March 2021 to January 2022. She served as General Manager, Thyroid & Urologic Cancers at Veracyte, Inc. since 2021 until January 6, 2022. She is President of Molecular Stethoscope, Inc. She was a Director at Olink Holding AB (publ) since January 2021 until April 7, 2022. She serves as Director of FirstString Research, Inc. She serves as Venture Partner and Advisory Board Member at Tullis Health Investors Inc. She supports the Tullis investment process at multiple levels including deal sourcing, deal review, due diligence and investment management. She served as President and Chief Executive Officer of Veracyte Sd, Inc. (formerly known as Decipher Biosciences, Inc.). since August 2018. She is an inventor on numerous scientific patents and serves on the Board of Directors Arena Pharmaceuticals, where she serves as Chair. She was an Independent Director of Exagen Inc. since July 30, 2019, until January 19, 2023. She serves as Executive Chairman of the Board of Directors at Exagen Inc. since January 19, 2023. She founded Genoptix Inc. in 2000 and served as its Chief Executive Officer since March 2000 until 2014 and President from March 2000 to April 2014. She co-founded Nanogen, Inc. where she served as Chief Operating Officer and President from 1994 to 2000, including during Nanogen's 1998 initial public offering and Selective Genetics, where she served as Chief Operating Officer from 1992 to 1994. She served as Chief Executive Officer and President at Molecular Stethoscope, Inc. from September 2015 to August 2018. She served as Senior Vice President of Oncology Business and General Manager of Oncology Business at Illumina Inc. from July 14, 2014, to August 2015. She served as a Consultant of Adamis Pharmaceuticals Corporation. From 1988 to 1992, she held various Director-level positions with Ligand Pharmaceuticals. She also held various research and management positions Nanogen, Inc. She held various research and management positions at Hybritech, Inc. a former subsidiary of Eli Lilly & Company from January 1984 to 1988. She has been involved in the co-founding of three life science companies in the San Diego biotechnology community. She was the Chair of the Board at Arena Pharmaceuticals, Inc. since June 13, 2016, until February 2021. She served as the Chairman and Director of Molecular Reflections. She served as an Executive Director of Genoptix Inc. from March 2000 to February 2011. From March 2000 to April 2014, Dr. Nova was a Co-Founder and Director, President and Chief Executive Officer of Genoptix Medical Laboratory, which was purchased by Novartis Pharmaceuticals Corporation in 2011. She had been Independent Director at OpGen, Inc. since April 24, 2017, until April 1, 2020. She serves as a Director of NeoStem Oncology, LLC. She is Vice Chairman of the Board of Directors for the newly formed Rady Pediatric Genomics and Systems Medicine Institute, which is part of Rady Children's Hospital-San Diego. She has been Director of Decipher Biosciences, Inc since August 2015. She has been Director of Synthetic Genomics Inc. since November 9, 2016. She is an Advisory Board Member of Tullis Health Investors Inc. She had been a Director of Arena Pharmaceuticals, Inc. since September 15, 2004, until March 11, 2022 and served as its Lead Independent Director since June 2015 until June 2016. She serves on the Advisory Boards of the UC San Diego Division of Biological Sciences, the Keck Graduate Institute of Applied Life Sciences Advisory Council and UC Irvine Division of Biological Sciences. Additionally, she serves on the Board of Trustees of University of San Diego. She served as an Executive Director of New Leads Discovery. She served as a Director of NanoString Technologies, Inc. from April 2014 to July 2014 and Adamis Pharmaceuticals Corporation from February 16, 2011 to August 2014. She served as a Director of Cyntellect Inc. She served as a Director of Heska Corporation since December 31, 2004 and Cypress Bioscience, Inc. since April 26, 2007. She is a successful entrepreneur with past work done in the biotechnology space. Dr. Nova Bennett was the winner of the 2004 BIOCOM James McGraw Distinguished Contribution Award, the 2004 Distinguished Alumnus Award UC Riverside, the 2003 Distinguished Alumnus Award UC Irvine, the 2002 Outstanding Executive Award UC San Diego Jacobs School of Engineering and the 2001 Athena Pinnacle Award. She received a B.Sc. degree in Biological Sciences at the University of California, Irvine, where she graduated with Honors. She also received Ph.D. in Biochemistry from the University of California, Riverside and conducted post- doctoral research at NYU Medical School.
Positions
- Company NameAurinia Pharmaceuticals Inc.Stock CodeAUPHPositionIndependent DirectorColleagues
- KCKevin C. TangChairman & CEO
- SPStephen P. RobertsonChief Legal Officer, Corporate Secretary & Chief Compliance Officer
- PSPeter S. GreenleafConsultant
- MSMichael S. HearneChief Financial Officer
- RCRyan ColeChief Operating Officer
- JAJeffrey Allen BaileyIndependent Director
- CACraig A. JohnsonLead Independent Director
- KLKathy L. GoetzIndependent Director
- Company NameAzenta, Inc.Stock CodeAZTAPositionIndependent DirectorColleagues
- MDMartin D. MadausInterim President, CEO & Director
- FEFrank E. CasalIndependent Chairman
- LYLawrence Y. LinExecutive VP & CFO
- ESEphraim StarrSenior VP, General Counsel & Corporate Secretary
- OPOlga PirogovaSenior VP & Chief HR Officer
- GZGinger ZhouAdvisor
- RCRobyn C. DavisIndependent Vice Chair of the Board
- EJErica J. McLaughlinIndependent Director
- TSTina S. NovaIndependent Director
- Company NameExagen Inc.Stock CodeXGNPositionExecutive Chairman of the Board of DirectorsColleagues
- TSTina S. NovaExecutive Chairman of the Board of Directors
- JAJohn AballiCEO, President & Director
- JGJeffrey G. BlackCFO & Corporate Secretary
- MMMichael MahlerChief Scientific Officer
- TJTina JacobsenVice President of Investor Relations
- AWArthur WeinsteinChairman of Scientific Advisory Board
- FSFrank StokesIndependent Director
- SDScott D. KahnIndependent Director
